ReviewInternational journal of cardiology. Cardiovascular risk and prevention2025
From resistant hypertension to renal denervation: an emerging therapeutic approach in light of new international guidelines.
Review in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Managing Arterial Hypertension in Chronic Renal Failure: Myths, Mechanisms, and Therapeutic Realities.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Resistant hypertension (RH) remains a major therapeutic challenge, affecting 12-18 % of treated hypertensive patients and associated with increased cardiovascular risk. Renal denervation (RDN) has emerged as a promising therapeutic option following initially mixed results. Objective: This review analyzes the evolution of RH management, from its definition to new therapeutic perspectives offered by RDN, based on recent international guidelines (ESH 2023, ESC 2024, ACC/AHA 2025). Methods: Critical analysis of pivotal clinical trials, recent meta-analyses, and international registries evaluating the efficacy and safety of RDN in RH. Results: Recent trials (SPYRAL HTN-ON/OFF MED, RADIANCE-HTN TRIO) demonstrate moderate but significant efficacy of RDN, with systolic blood pressure reductions ranging from 3.9 to 18.7 mmHg depending on populations. Technological advances (multi-electrode catheters, distal branch targeting) improve outcomes. The safety profile appears favorable with low complication rates. Conclusions: RDN represents an emerging therapeutic option for RH, now recommended by European societies for specific indications. Rigorous patient selection and performance in experienced centers remain essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.